SPARC Immunoassay for Distinguishing Lung Cancer From IPF
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to accurately distinguish between lung cancer and other fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF), and there is a need for a sensitive assay that can monitor the progression of these conditions effectively.
Innovation Solution
A highly sensitive immunoassay using a monoclonal antibody specifically reactive with the N-terminus amino acid sequence LLARDFEKNY, which does not bind to N-extended or N-truncated versions of this sequence, allowing for the detection and monitoring of lung cancer and IPF by quantifying peptide binding levels in patient biofluids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used to distinguish lung cancer from fibrotic diseases, then diagnostic procedures become invasive, but measurement precision and early detection capability deteriorate
Solution Approach 1:
The patent replaces invasive mechanical diagnostic procedures (biopsies, surgical interventions) with a biochemical detection system using monoclonal antibodies that specifically bind to SPARC protein in biofluid samples, enabling non-invasive detection of lung cancer and IPF through blood or other fluid analysis
Solution Approach 2:
The patent introduces monoclonal antibodies as intermediary molecules that specifically recognize and bind to the SPARC protein marker in patient biofluids, serving as a mediator between the diagnostic system and the disease state, allowing indirect but highly specific detection without direct tissue intervention
2Adaptability or versatility
If current assays are used to monitor disease progression, then diagnostic utility is limited, but the ability to distinguish between different conditions deteriorates
Solution Approach 1:
The patent applies local quality by designing a monoclonal antibody with highly specific binding characteristics targeted at a particular epitope region of the SPARC protein, enabling the assay to distinguish between different diseases (lung cancer versus IPF) based on localized molecular recognition rather than general protein detection
3Measurement precision
If early detection capabilities are enhanced, then diagnostic accuracy improves, but the complexity of the assay increases
Solution Approach 1:
The patent extracts and isolates a specific functional element - the monoclonal antibody with defined specificity for the SPARC N-terminus - from the complex mixture of proteins and markers in biofluids, allowing early detection through targeted binding that simplifies the overall diagnostic approach while maintaining high accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay provides excellent diagnostic utility for lung cancer and IPF, enabling early detection and potentially reducing the need for invasive procedures, and allows monitoring of treatment response and efficacy.
Implementation Method 1
contacting a patient biofluid sample with a monoclonal antibody specifically reactive with an N-terminus amino acid sequence (SEQ ID NO: 1)LLARDFEKNY
Data Source
AI summary
The present invention relates to an assay for detecting secreted proteome acidic and rich in cysteine (SPARC), and more specifically to its use in evaluating lung cancer.